| Literature DB >> 30728286 |
Alessandro Prestipino1,2, Robert Zeiser3.
Abstract
Treatment with immune checkpoint inhibitors targeting programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) is effective in many cancer types. Tumors harboring specific mutations modulate antitumor immune responses through the PD-1/PD-L1 axis, and this should be taken into account when designing rational combinatory treatments.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30728286 DOI： 10.1126/scitranslmed.aav4810
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956